Phase 1
Days after Axovant announced an end to focusing on its legacy small molecule portfolio in favor of gene therapies, the company announced it has licensed worldwide rights to two gene therapy programs from the University of Massachusetts School of Medicine.
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067
ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial
Medigene AG announced that researchers from Oslo University Hospital presented an update on clinical compassionate use (1) data of their dendritic cell (DC) vaccine utilizing Medigene’s DC vaccine technology for production.
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.
At the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, Amgen released the first clinical data from two separate Phase I clinical trials of novel BiTE immunotherapies.
Karolinska Development’s portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US.
PRESS RELEASES